Lab
Traditionally antibodies have been considered the gold standard of targeting ligands, able to specifically target desired cellular targets with high affinity. Aptamers, small nucleic acid ligands, are targeting ligands with antibody-like affinities and specificities at a fraction of the size. Our lab selects novel aptamers against different disease targets and utilizes the unique properties of the aptamers to better detect, image and treat diseases. This involves the use of both in vitro biological aptamer selection techniques as well as oligonucleotide synthesis methods. Our ultimate goal is to develop new clinically relevant therapeutic and imaging agents to improve patient outcomes.
Lab Website: Powell Gray Lab
Technology Expertise Keywords
Aptamers; RNA therapeutics; Imaging
Selected Publications
View all on PubMed
Gray BP*, Song X*, Hsu DS, Kratschmer C, Levy M Barry AP and Sullenger BA. An Aptamer for Broad Cancer Targeting and Therapy. Cancers. 2020; 12(11):3217. * Co-first authors. PMID – 33142831
Gray BP, Requena MA, Nichols M and Sullenger BA. Aptamers as Reversible Sorting Ligands for Preparation of Cells in their Native State. Cell Chem Biol. 2020; 27:232-244. PMID - 31879266
Powell Gray B, Kelly L, Ahrens D, Barry A, Kratschmer C, Levy M and Sullenger BA. Tunable Cytotoxic Aptamer-Drug Conjugates for the Treatment of Prostate Cancer. PNAS. 2018; 115(18):4761-4766. PMID - 29666232
Gray BP and Brown KC. Combinatorial Peptide Libraries: Mining for Cell-Binding Peptides. Chemical Reviews. 2014; 114(2):1020-1081. PMID - 24299061
Gray BP, McGuire MJ, and Brown KC. A Liposomal Drug Platform Overrides Peptide Ligand Targeting to a Cancer Biomarker, Irrespective of Ligand Affinity or Density. PLoS One. 2013; 8(8):e72938. PMID - 24009717
